Learn what we know so far about its potential benefits, optimal dosage, side effects, and safety
Why brain-based GLP-1 activity matters clinically: It helps explain the appetite-suppressing effects of GLP-1 receptor agonist medications It may contribute to neuroprotective mechanisms being investigated in neurodegenerative diseases It potentially influences cognitive processes and mood regulation, though human evidence remains limited It provides insight into the gut-brain axis and metabolic-neurological interactions Understanding GLP-1's cerebral actions has become particularly relevant as GLP-1 receptor agonistsoriginally developed for type 2 diabetesare now also licensed for weight management in the UK (NICE TA875, TA664)
Constipation: Wegovy 2.4 mg: 24% (STEP 1) Zepbound 10 mg: 9% (SURMOUNT-1) Tirzepatide produces significantly lower constipation rates
Adults age 65 and older made up 37% of the study group but accounted for 53% of hypotensive events
8 weeks 56 syringes 1 per day 12 weeks 84 syringes 1 per day 16 weeks 112 syringes 1 per day Bacteriostatic Water Use 3.0 mL per vial for reconstitution
The dose-dependent effect of GLP-1 on decelerating gastric emptying plays a substantial role in improving postprandial glycemic concentrations to the extent that postprandial insulin secretion may no longer be stimulated or could even be reduced (154, 155) ( Figure 1 Section D)
